Methods and Composition for Diagnosing and Preventing a Group B Streptococcal Infection (SJ-02-0032)

Technology Name
(St. Jude Reference #)
Group B streptococcus, Epsilon antigen, vaccine
Description Group B streptococci (GBS) causes life-threatening infections in newborns and affects about 1 in every 2,000 babies in the United States.  Not every baby who is born to a mother who tests positive for GBS will become ill and researchers at the University of Florida, University of Utah and St. Jude Children's Research Hospital have discovered an immunologic marker useful for diagnosing a highly virulent GBS infection.  They identified a novel surface antigen, designated epsilon antigen, on GBS which encodes a unique serine-rich repeat protein (ssr-2) that is expressed by the highly pathogenic RDP III-3 lineage.  This protein is a useful diagnostic marker for the pathogenic form of the disease and a good candidate for vaccine development.
Keywords Group B streptococcus, Epsilon antigen, vaccine
Granted Patents or Published Applications US Patent No. 7,588,773
Related Scientific References Seifert KN, et al; "A unique serine-rich repeat protein (srr) and novel surface antigen (epsilon) associated with a virulent lineage of serotype III Streptococcus agalactiae" Microbiology 152(Pt4):102901040 (2006).
Licensing Opportunities This invention is co-owned with the University of
Florida and the University of Utah. We are currently seeking licensing opportunities in all fields for the development
of this technology.


Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.


Last update: August 2013